background
mice
lack
type
interferon
receptor
ifnar
mice
reproduc
relev
aspect
crimeancongo
hemorrhag
fever
cchf
human
includ
liver
damag
aim
character
liver
patholog
cchf
virusinfect
ifnar
mice
immunohistochemistri
employ
model
evalu
antivir
efficaci
ribavirin
arbidol
cchf
viru
methodologyprincip
find
cchf
virusinfect
ifnar
mice
die
day
post
infect
elev
aminotransferas
level
high
viru
titer
blood
organ
main
patholog
alter
acut
hepat
extens
bridg
necrosi
reactiv
hepatocyt
prolifer
mild
moder
inflammatori
respons
monocytemacrophag
activ
virusinfect
apoptot
hepatocyt
cluster
necrot
area
ribavirin
arbidol
suppress
viru
replic
vitro
log
unit
ic
mgml
ic
mgml
ribavirin
mg
increas
surviv
rate
ifnar
mice
prolong
time
death
reduc
aminotransferas
level
viru
titer
arbidol
mg
efficaci
vivo
anim
treat
h
mg
day
mg
post
infect
surviv
show
sign
diseas
viru
blood
organ
coadministr
ribavirin
yield
benefici
rather
advers
effect
conclusionssignific
activ
hepat
macrophag
monocytederiv
cell
may
play
role
proinflammatori
cytokin
respons
cchf
cluster
infect
hepatocyt
necrot
area
without
mark
inflamm
suggest
viral
cytopath
effect
highli
potent
cchf
viru
vitro
vivo
vivo
efficaci
exce
current
standard
drug
treatment
cchf
ribavirin
crimeancongo
hemorrhag
fever
viru
cchfv
negativestrand
rna
viru
belong
genu
nairoviru
famili
bunyavirida
viru
endem
africa
asia
southeast
europ
middl
east
hyalomma
tick
transmit
viru
human
wildlif
livestock
human
may
also
infect
contact
infect
livestock
humantohuman
transmiss
occur
mainli
hospit
set
human
viru
caus
febril
ill
may
associ
hemorrhag
liver
necrosi
shock
multiorgan
failur
hallmark
diseas
increas
level
serum
aspart
alanin
aminotransferas
ast
alt
respect
thrombocytopenia
dissemin
intravascular
coagulopathi
averag
case
fatal
rate
may
higher
nosocomi
outbreak
pathophysiolog
diseas
poorli
understood
endotheli
liver
cell
damag
induct
proinflammatori
cytokin
dysregul
coagul
cascad
thought
play
role
studi
pathophysiolog
crimeancongo
hemorrhag
fever
cchf
hamper
lack
appropri
anim
model
mammal
fulli
function
immun
system
describ
farexcept
human
develop
diseas
upon
infect
first
anim
model
neonat
mous
recent
two
transgen
mous
model
cchf
describ
first
mice
lack
signal
transduc
activ
transcript
mice
second
mice
lack
type
alphabeta
interferon
receptor
ifnar
mice
knockout
mice
defect
innat
immun
respons
die
rapidli
cchfv
infect
reproduc
relev
aspect
human
cchf
surrog
model
cchf
employ
ifnar
mice
infect
dugb
hazara
viru
two
cchfvrelat
nairovirus
known
caus
diseas
human
work
model
carri
biosafeti
level
bsl
work
infecti
cchfv
requir
facil
present
studi
aim
character
patholog
chang
liver
cchfvinfect
ifnar
mice
detail
furthermor
employ
model
evalu
antivir
efficaci
ribavirin
arbidol
favipiravir
cchfv
vivo
drug
either
clinic
use
advanc
stage
clinic
test
ribavirin
inhibit
cchfv
replic
cell
cultur
administ
cchf
patient
though
clinic
benefit
proven
discuss
controversi
show
benefici
effect
neonat
mous
model
ribavirin
current
drug
avail
treatment
cchf
arbidol
broadspectrum
antivir
show
activ
rang
rna
virus
vitro
vivo
notabl
influenza
viru
russia
china
drug
clinic
use
primarili
prophylaxi
treatment
acut
respiratori
infect
includ
influenza
arbidol
assum
act
via
hydrophob
interact
membran
viru
protein
thu
inhibit
viral
fusion
entri
potent
inhibitor
vitro
anim
model
influenza
viru
phlebovirus
hantavirus
arenavirus
alphavirus
picornavirus
noroviru
follow
convers
presum
act
nucleotid
analog
select
inhibit
viral
rnadepend
rna
polymeras
caus
lethal
mutagenesi
upon
incorpor
viru
rna
favipiravir
current
late
stage
clinic
develop
treatment
influenza
viru
infect
studi
carri
strict
accord
recommend
german
societi
laboratori
anim
scienc
supervis
veterinarian
protocol
approv
committe
ethic
anim
experi
citi
hamburg
permit
effort
made
minim
number
anim
use
experi
suffer
anim
experi
staff
carri
anim
experi
pass
educ
train
program
accord
categori
b
c
feder
european
laboratori
anim
scienc
associ
anim
experi
studi
report
accord
arriv
guidelin
total
mice
use
studi
mice
includ
analysi
cchfv
strain
isol
laboratori
patient
fatal
cours
infect
passag
time
use
studi
viru
stock
grown
vero
cell
quantifi
immunofocu
assay
see
store
use
vitro
vivo
experi
ribavirin
ca
pubchem
cid
obtain
mp
biomed
order
arbidol
hydrochlorid
ca
pubchem
cid
waterston
technolog
usa
order
favipiravir
ca
pubchem
cid
custom
synthes
boc
scienc
creativ
dynam
usa
compound
dissolv
dimethyl
sulfoxid
dmso
concentr
mgml
store
final
dmso
concentr
cell
cultur
supernat
vero
cell
grown
dulbecco
modifi
eagl
medium
dmem
paa
laboratori
supplement
fetal
calf
serum
fc
streptomycinpenicillin
seed
densiti
cell
per
well
plate
day
infect
cell
inocul
cchfv
multipl
infect
moi
laboratori
inoculum
remov
h
replac
fresh
medium
complement
differ
concentr
compound
arbidol
experi
cell
addit
pretreat
arbidol
h
infect
concentr
cell
cultur
supernat
infecti
viru
particl
measur
day
post
infect
pi
immunofocu
assay
cell
growth
viabil
compound
treatment
determin
mtt
method
describ
sigmoid
doserespons
curv
fit
data
use
prism
graphpad
graphpad
softwar
inhibitori
concentr
reduc
viru
titer
ic
ic
ic
respect
cytotox
concentr
reduc
cell
growth
cc
cc
respect
calcul
sigmoid
function
analysi
combin
two
drug
concentr
matrix
test
drug
x
test
crimeancongo
hemorrhag
fever
cchf
endem
africa
asia
southeast
europ
middl
east
case
fatal
rate
studi
pathophysiolog
treatment
cchf
hamper
lack
appropri
anim
model
employ
cchf
virusinfect
transgen
mice
defect
innat
immun
respons
diseas
model
mice
die
infect
show
sign
diseas
similar
found
human
first
studi
liver
patholog
anim
hepat
necrosi
promin
featur
human
cchf
secondli
use
model
test
efficaci
antivir
drug
clinic
use
advanc
stage
clinic
test
besid
ribavirin
standard
drug
treatment
cchf
test
arbidol
drug
clinic
use
respiratori
infect
new
drug
clinic
develop
treatment
influenza
viru
infect
ribavirin
arbidol
show
benefici
effect
respect
highli
efficaci
anim
model
data
hold
promis
clinic
efficaci
human
cchf
concentr
c
ic
ic
ic
ic
ic
ic
ic
possibl
combin
c
x
c
ic
valu
deriv
prior
singledrug
experi
drug
combin
data
analyz
use
bliss
independ
drug
interact
model
model
defin
equat
e
xy
e
x
e
e
x
ne
e
xy
addit
effect
drug
x
predict
individu
effect
e
x
e
e
x
v
ob
ob
c
x
v
ob
e
v
ob
ob
c
v
ob
v
ob
c
x
c
observ
ie
experiment
determin
viru
titer
c
x
c
analog
macsynergi
ii
program
evalu
antiviru
data
accord
bliss
independ
model
threedimension
approach
use
identifi
area
observ
effect
greater
synergi
less
antagon
predict
e
xy
end
ratio
predict
viru
titer
v
pred
c
x
c
v
ob
n
xy
observ
viru
titer
v
ob
c
x
c
calcul
drug
combin
c
x
c
ratio
indic
synergi
ie
c
x
c
viru
titer
predict
addit
effect
higher
experiment
determin
viru
titer
ratio
indic
antagon
ie
c
x
c
viru
titer
predict
addit
effect
lower
experiment
determin
viru
titer
ifnar
mice
background
bred
specif
pathogen
free
anim
facil
bernhardnochtinstitut
six
twelveweekold
femal
anim
weight
median
g
rang
g
use
experi
except
nine
male
use
determin
lethal
viru
dose
group
size
anim
expect
provid
suffici
accur
estim
surviv
rate
viremia
clinic
chemistri
paramet
allow
detect
differ
surviv
rate
control
treatment
group
p
alpha
power
beta
experiment
group
agematch
three
five
anim
group
kept
togeth
convent
cage
without
enrich
ad
libitum
access
food
water
infect
experi
cchfv
perform
anim
facil
laboratori
artifici
lightdark
cycl
three
ten
anim
per
group
depend
whether
organ
collect
plan
infect
intraperiton
ip
inject
focu
form
unit
ffu
cchfv
ml
dmem
contain
fc
mode
administr
chosen
facilit
compar
previous
describ
cchf
mous
model
infect
mice
monitor
daili
sign
diseas
bodi
weight
rectal
bodi
temperatur
measur
use
thermomet
rectal
probe
mice
bioseb
franc
anim
sever
sign
diseas
seizur
bleed
abdomin
distent
diarrhea
agoni
weight
loss
within
day
euthan
blood
sampl
ml
per
anim
drawn
tail
vein
punctur
interv
day
period
day
blood
draw
total
clinic
chemistri
viremia
measur
organ
collect
criteria
euthanasia
fulfil
end
experi
anim
euthan
isofluran
overdos
follow
cervic
disloc
organ
collect
death
day
pi
anim
randomli
chosen
experiment
group
anim
analyz
infecti
viru
titer
histopatholog
chang
experi
replic
ribavirin
administ
daili
ip
rout
stock
mgml
nacl
prepar
applic
anim
receiv
ribavirin
dose
mg
ml
mous
ml
nacl
placebo
ribavirin
dose
fatal
mice
ld
mg
treatment
commenc
h
pi
continu
death
day
arbidol
administ
daili
per
os
use
stomach
probe
suspens
mgml
methylcellulos
prepar
applic
anim
receiv
arbidol
dose
mg
ml
suspens
mous
ml
methylcellulos
placebo
treatment
commenc
day
infect
continu
death
day
vivo
toxic
arbidol
evalu
uninfect
anim
treat
mg
day
toxic
effect
observ
dose
rang
administ
twice
daili
per
os
use
stomach
probe
suspens
mgml
methylcellulos
prepar
daili
anim
receiv
dose
mg
ml
suspens
twice
daili
mous
ml
methylcellulos
twice
daili
treatment
commenc
h
pi
later
continu
death
day
infecti
viru
particl
blood
organ
sampl
determin
immunofocu
assay
organ
sampl
homogen
ml
fc
use
lyse
matrix
mp
biomed
beat
mill
vero
cell
plate
inocul
ml
serial
dilut
sampl
inoculum
remov
h
replac
fc
overlay
day
incub
cell
fix
formaldehyd
phosphatebuff
salin
pb
wash
water
permeabil
triton
pb
wash
block
fc
pb
infect
cell
foci
detect
cchfv
nucleoprotein
np
specif
monoclon
antibodi
wash
cell
incub
peroxidaselabel
antimous
igg
foci
visual
tetramethylbenzidin
count
virusspecif
antibodi
blood
detect
immunofluoresc
assay
ifa
use
cell
infect
cchfv
strain
antigen
mous
serum
inactiv
h
test
dilut
serum
sampl
dilut
higher
requir
nacl
analyz
ast
alt
activ
use
commerci
avail
colorimetr
assay
kit
detect
limit
undilut
serum
ul
ast
ul
alt
reflotron
roch
diagnost
paramet
measur
individu
anim
lung
kidney
heart
spleen
brain
liver
collect
fix
formaldehyd
pb
embed
paraffin
use
leica
tissu
processor
leica
embed
station
leica
section
mm
stain
hematoxylineosin
h
e
process
immunohistochemistri
ihc
ihc
section
stain
use
ventana
benchmark
xt
autom
stain
system
ventana
medic
system
cell
condit
solut
ventana
min
section
incub
primari
antibodi
direct
b
cell
marker
ebiosci
apoptosi
marker
cleav
r
system
cell
marker
dako
myeloidlineag
cell
eg
macrophag
marker
wako
chemic
induc
nitric
oxid
synthas
ino
express
activ
monocytederiv
cell
abcam
cell
prolifer
marker
abcam
h
primari
figur
surviv
bodi
weight
ast
alt
viru
titer
blood
organ
ifnar
mice
infect
differ
dose
cchfv
mice
inocul
ip
ffu
viru
organ
titer
determin
anim
succumb
infect
euthan
due
sever
diseas
mean
standard
deviat
shown
weight
logtransform
organ
titer
vertic
bar
graph
ast
alt
note
log
scale
yaxi
logtransform
viru
titer
blood
repres
mean
valu
data
ffu
group
anim
pool
correspond
data
placebo
control
shown
fig
provid
reliabl
estim
paramet
rang
viremia
detect
limit
immunofocusassay
well
normal
refer
rang
ast
alt
mice
shade
grey
note
ffu
group
surviv
anim
show
neither
astalt
elev
viremia
day
alt
valu
one
anim
determin
ffu
group
anim
die
day
show
astalt
elev
viremia
day
antibodi
detect
antimous
igg
antirabbit
igg
antirat
igg
histofin
simpl
stain
max
po
immunoenzym
polym
nichirei
bioscienc
stain
dab
substrat
use
ultraview
univers
dab
detect
kit
ventana
cell
counterstain
hematoxylin
ihc
primari
antibodi
direct
cchfv
np
monoclon
antibodi
neutrophil
marker
bd
bioscienc
perform
manual
section
boil
citrat
buffer
ph
h
incub
antibodi
overnight
primari
antibodi
detect
antimous
igg
histofin
simpl
stain
ap
antirat
igg
histofin
simpl
stain
max
po
immunoenzym
polym
stain
fast
red
roch
dab
sigmaaldrich
substrat
respect
mayer
hematoxylin
solut
use
counterstain
section
coverslip
tissu
tek
mount
medium
sakura
finetek
statist
analysi
perform
graphpad
graphpad
softwar
unpair
group
compar
twotail
mannwhitney
u
test
continu
paramet
twotail
fisher
exact
test
frequenc
surviv
curv
compar
logrank
mantelcox
test
test
antivir
ifnar
mous
model
aim
determin
optim
infect
dose
cchfv
strain
character
diseas
caus
particular
strain
end
ifnar
mice
infect
ip
ffu
anim
die
infect
even
inocul
ffu
inoculum
die
infect
ffu
ffu
ffu
ffu
ffu
ffu
ffu
indic
infecti
viru
particl
cchfv
strain
suffici
initi
product
infect
lethal
outcom
consist
observ
ffu
therefor
model
character
inocul
dose
ffu
fig
anim
infect
ffu
die
day
anim
infect
histopatholog
distribut
viral
antigen
liver
spleen
cchfvinfect
ifnar
mice
effect
treatment
ribavirin
anim
inocul
ip
ffu
cchfv
top
liver
collect
anim
ii
anim
succumb
infect
without
treatment
day
pi
iii
succumb
infect
day
pi
follow
ribavirin
treatment
mg
iv
euthan
day
pi
treatment
mg
treatment
ribavirin
commenc
h
pi
continu
death
day
bottom
spleen
collect
anim
anim
succumb
infect
without
treatment
day
pi
section
stain
h
e
distribut
cchfv
tissu
visual
use
monoclon
antibodi
cchfv
np
histopatholog
find
repres
anim
analyz
per
group
scale
bar
mm
ffu
uniformli
die
day
death
anim
lost
bodi
weight
fig
day
mean
ast
alt
valu
around
ul
ul
respect
anim
inocul
ffu
valu
higher
ffu
group
ast
ul
alt
ul
fig
ast
alt
elev
indic
cell
damag
particular
liver
cell
day
viru
titer
blood
rang
detect
lime
ffu
group
via
log
ffuml
ffu
group
log
ffuml
ffu
group
fig
day
viru
found
organ
analyz
spleen
kidney
liver
heart
lung
brain
titer
rang
log
ffug
irrespect
inocul
dose
fig
maximum
viru
concentr
found
liver
inocul
ffu
uniformli
lethal
inocul
ffu
leav
day
infect
lethal
outcom
therapeut
intervent
experi
conduct
dose
ffu
lung
heart
kidney
brain
liver
spleen
cchfvinfect
ifnar
mice
collect
day
assess
h
estain
section
viru
distribut
organ
inflammatori
respons
liver
visual
ihc
ifnar
mice
serv
control
liver
liver
cchfvinfect
ifnar
mice
show
acut
hepat
extens
bridg
hepatocellular
necrosi
mild
moder
inflammatori
respons
fig
necrot
area
accumul
cchfv
np
hepatocyt
fig
cleav
apoptot
hepatocyt
detect
fig
cell
prolifer
determin
stain
nuclear
antigen
increas
although
cell
could
attribut
inflammatori
respons
prolifer
hepatocyt
also
evid
fig
architectur
macrophag
kupffer
cell
necrot
area
disturb
cell
show
enlarg
cell
bodi
focal
cluster
fig
addit
inosexpress
activ
monocytederiv
cell
present
normal
liver
detect
fig
alter
suggest
monocyt
macrophag
activ
number
cell
b
cell
granulocyt
slightli
increas
fig
spleen
spleen
cchfvinfect
mice
show
moder
decreas
number
lymphocyt
increas
amount
cell
debri
red
white
pulp
furthermor
number
megakaryocyt
decreas
fig
cchfv
np
detect
spleen
cell
although
signal
much
less
intens
liver
fig
lung
heart
kidney
brain
histopatholog
analysi
reveal
obviou
differ
lung
heart
kidney
brain
tissu
cchfvinfect
mice
viru
antigen
level
detect
limit
ihc
data
shown
summari
ifnar
mice
infect
cchfv
show
patholog
chang
liver
spleen
main
find
acut
hepat
extens
necrosi
reactiv
prolifer
hepatocyt
mild
moder
inflammatori
respons
figur
ihc
marker
inflamm
apoptosi
prolifer
liver
cchfvinfect
ifnar
mice
effect
treatment
ribavirin
anim
inocul
ip
ffu
cchfv
liver
collect
anim
ii
anim
succumb
infect
without
treatment
day
pi
iii
succumb
infect
day
pi
follow
ribavirin
treatment
mg
iv
euthan
day
pi
treatment
mg
treatment
ribavirin
commenc
h
pi
continu
death
day
section
stain
antibodi
ino
cleav
cell
mark
arrow
antibodi
show
spuriou
crossreact
histopatholog
find
repres
anim
analyz
per
group
scale
bar
mm
vivo
efficaci
antivir
cchf
viru
plo
neglect
tropic
diseas
wwwplosntdsorg
figur
treatment
cchfvinfect
ifnar
mice
ribavirin
arbidol
hydrochlorid
mice
inocul
ip
ffu
viru
ribavirin
administ
ip
daili
anim
receiv
ribavirin
dose
mg
nacl
placebo
treatment
commenc
h
pi
continu
death
day
arbidol
administ
daili
per
os
use
stomach
probe
anim
receiv
arbidol
dose
mg
methylcellulos
placebo
treatment
commenc
day
infect
continu
death
day
organ
titer
determin
anim
succumb
infect
euthan
due
sever
diseas
addit
three
anim
ribavirintr
group
randomli
euthan
day
pi
determin
viru
titer
organ
weight
ast
alt
viremia
data
obtain
mice
day
includ
respect
graph
mean
standard
deviat
shown
weight
logtransform
organ
titer
vertic
bar
graph
ast
alt
note
log
scale
yaxi
logtransform
viru
titer
blood
repres
mean
valu
durat
treatment
surviv
plot
rang
viremia
detect
morpholog
sign
monocytemacrophag
activ
cchfvinfect
apoptot
hepatocyt
cluster
necrot
area
antivir
activ
ribavirin
arbidol
hydrochlorid
cchfv
strain
test
vero
cell
three
compound
abl
suppress
viru
replic
log
unit
concentr
mgml
fig
ic
ic
valu
rang
mgml
mgml
respect
ic
valu
rang
mgml
cell
toxic
test
rang
measur
mtt
test
evid
arbidol
hydrochlorid
ribavirin
cc
mgml
arbidol
hydrochlorid
cc
mgml
cc
mgml
cc
mg
ml
fig
conclus
three
compound
show
potent
antivir
effect
cchfv
cell
cultur
arbidol
display
toxic
therapeut
index
ribavirin
test
comparison
placebo
group
receiv
vehicl
nacl
solut
fig
group
ifnar
mice
infect
ffu
cchfv
although
one
anim
surviv
treatment
ribavirin
significantli
increas
surviv
rate
p
howev
drug
prolong
time
death
median
vs
day
placebo
vs
ribavirin
p
reduc
level
ast
p
alt
p
day
reduc
viru
titer
blood
day
p
increas
weight
day
p
p
respect
reduc
termin
viru
concentr
organ
compar
placebo
day
separ
organ
histopatholog
analysi
organ
collect
day
ribavirintr
mice
reveal
small
dissemin
foci
necrosi
liver
parenchyma
resembl
mice
markedli
reduc
hepatocellular
necrosi
correl
low
number
apoptot
hepatocyt
cleav
tcell
bcell
activ
monocytederiv
cell
ino
viru
antigenposit
cell
np
significantli
reduc
liver
spleen
compar
untreat
placebotr
mice
data
shown
howev
ribavirintr
mice
succumb
infect
day
show
extens
bridg
hepatocellular
necrosi
time
death
fig
like
untreat
mice
necrosi
accompani
presenc
numer
macrophag
kupffer
cell
show
enlarg
cell
bodi
focal
cluster
inosexpress
activ
monocytederiv
cell
fig
alter
suggest
strong
monocytemacrophag
activ
howev
contrast
untreat
mice
viru
antigen
hardli
detect
liver
tissu
treat
mice
fig
consist
low
viru
titer
organ
fig
bottom
thu
ribavirin
reduc
cchfv
load
delay
diseas
progress
prevent
termin
liver
necrosi
monocytemacrophag
activ
lethal
outcom
ifnar
mous
model
arbidol
hydrochlorid
mg
test
comparison
placebo
group
receiv
vehicl
methylcellulos
fig
data
shown
mg
group
infect
ffu
cchfv
mice
pretreat
one
day
inocul
howev
drug
chang
neither
surviv
rate
surviv
time
paramet
measur
even
reduc
inocul
dose
ffu
effect
compar
histor
control
group
test
comparison
placebo
group
receiv
vehicl
methylcellulos
fig
group
infect
ffu
cchfv
initi
high
dose
mg
test
drug
administ
day
day
placebotr
anim
die
day
day
show
weight
loss
nearli
increas
bodi
temperatur
ast
valu
ul
alt
valu
ul
anim
treatment
group
surviv
infect
show
sign
diseas
viru
detect
neither
blood
organ
throughout
observ
period
fig
data
shown
histopatholog
ihc
day
reveal
larg
normal
liver
tissu
absenc
viru
antigen
inflammatori
cell
fig
determin
efficaci
drug
advanc
stage
infect
timeofaddit
experi
perform
fig
treatment
high
dose
drug
commenc
day
day
viru
inocul
continu
day
surviv
group
anim
show
hardli
sign
diseas
treatment
start
day
pi
minor
chang
weight
temperatur
ast
seen
day
viru
remain
undetect
blood
organ
timeofaddit
group
throughout
observ
period
provid
evid
infect
anim
treatment
group
develop
cchfvspecif
antibodi
measur
day
pi
anim
treat
postexposur
anim
treat
day
pi
develop
antibodi
indic
viru
replic
postexposur
treatment
even
suffici
elicit
antibodi
defin
lowest
effect
dose
anim
receiv
mg
methylcellulos
placebo
fig
treatment
commenc
h
pi
continu
death
day
anim
mg
treatment
group
surviv
show
hardli
sign
diseas
viru
detect
low
level
blood
one
anim
mg
treatment
group
day
fig
dose
mg
prevent
lethal
outcom
although
prolong
time
death
p
reduc
level
ast
p
alt
p
day
togeth
highli
effici
cchfv
ifnar
mous
model
ribavirin
current
clinic
use
treatment
cchf
therefor
import
know
could
given
combin
ribavirin
drug
interact
first
antivir
activ
combin
ribavirin
determin
cell
cultur
concentr
matrix
design
around
ic
valu
drug
determin
infecti
viru
particl
measur
day
pi
immunofocu
assay
cell
viabil
determin
mtt
method
doserespons
surfac
demonstr
combin
ribavirin
exhibit
strong
antivir
effect
suppress
viru
replic
log
unit
fig
possibl
limit
immunofocusassay
well
normal
refer
rang
ast
alt
mice
shade
grey
note
ffu
placebo
group
anim
die
day
show
astalt
elev
viremia
day
ffu
ribavirin
group
surviv
anim
show
detect
viremia
ast
elev
viremia
determin
day
ffu
arbidol
group
surviv
anim
ast
elev
viremia
day
valu
day
determin
due
insuffici
amount
blood
antagonist
synergist
effect
evalu
use
bliss
independ
model
analog
algorithm
macsynergi
ii
program
analysi
reveal
clear
synergist
effect
drug
combin
concentr
around
ic
area
matrix
experiment
viru
titer
log
unit
lower
titer
figur
treatment
cchfvinfect
ifnar
mice
timeofaddit
experi
mice
inocul
ip
ffu
viru
administ
twice
daili
per
os
use
stomach
probe
anim
receiv
dose
mg
methylcellulos
placebo
treatment
commenc
h
day
day
pi
continu
death
day
two
anim
per
treatment
regimen
euthan
day
pi
determin
viru
titer
organ
mean
standard
deviat
shown
weight
temperatur
vertic
bar
graph
ast
alt
note
log
scale
yaxi
logtransform
viru
titer
blood
repres
mean
valu
durat
treatment
surviv
plot
rang
viremia
detect
limit
immunofocusassay
well
normal
refer
rang
ast
alt
mice
shade
grey
figur
definit
lowest
effect
dose
mice
inocul
ip
ffu
viru
administ
twice
daili
per
os
use
stomach
probe
anim
receiv
dose
mg
methylcellulos
placebo
treatment
commenc
h
pi
continu
death
day
viru
titer
organ
determin
anim
succumb
infect
anim
mg
group
euthan
day
organ
analysi
done
mg
group
nd
mean
standard
deviat
rang
n
shown
weight
temperatur
logtransform
organ
titer
vertic
bar
graph
ast
predict
accord
bliss
independ
model
addit
effect
fig
mtt
test
reveal
drug
toxic
whole
matrix
fig
test
effect
drug
combin
vivo
anim
receiv
dose
mg
combin
ribavirin
dose
mg
mg
dose
protect
upon
singledrug
administr
chosen
test
addit
ribavirin
interfer
efficaci
explor
combin
two
subeffect
dose
may
result
effect
treatment
mg
mg
ribavirin
coadminist
none
paramet
mg
plu
mg
ribavirin
group
fig
left
statist
significantli
differ
paramet
mg
singledrug
group
fig
hand
combin
mg
dose
mg
dose
ribavirin
fig
right
improv
surviv
rate
compar
singledrug
treatment
fig
although
increas
reach
statist
signific
p
vs
alon
p
vs
ribavirin
alon
twotail
fisher
exact
test
conclus
ribavirin
exert
synergist
effect
accord
bliss
independ
model
combin
concentr
around
ic
vitro
coadministr
drug
anim
model
suggest
combin
treatment
yield
benefici
rather
advers
effect
studi
use
ifnar
mice
vivo
model
evalu
efficaci
antivir
cchfv
main
patholog
alter
mice
infect
recent
isol
cchfv
strain
acut
hepat
extens
necrosi
reactiv
prolifer
hepatocyt
mild
moder
inflammatori
respons
morpholog
sign
monocyt
macrophag
activ
cchfvinfect
apoptot
hepatocyt
found
necrot
area
ribavirin
arbidol
hydrochlorid
activ
cchfv
cell
cultur
howev
arbidol
hydrochlorid
inact
vivo
ribavirin
partial
activ
highli
effici
mous
model
latter
drug
effect
even
window
therapeut
intervent
less
day
three
mous
model
cchf
describ
past
neonat
mous
model
mice
ifnar
mice
latter
model
take
advantag
defect
innat
immun
respons
appar
essenti
protect
mice
product
cchfv
infect
three
model
mice
die
infect
within
day
prefer
work
ifnar
mice
genet
defect
concern
interferon
type
signal
defici
prevent
upregul
gene
due
signal
either
type
type
ii
interferon
neonat
mice
alt
note
log
scale
yaxi
logtransform
viru
titer
blood
repres
mean
valu
durat
treatment
surviv
plot
rang
viremia
detect
limit
immunofocusassay
well
normal
refer
rang
ast
alt
mice
shade
grey
note
placebo
group
anim
die
day
show
astalt
elev
viremia
day
mg
group
surviv
anim
show
neither
astalt
elev
viremia
time
threedimension
approach
use
identifi
area
observ
effect
greater
synergi
less
antagon
predict
bliss
independ
model
end
ratio
predict
viru
titer
observ
viru
titer
calcul
drug
combin
ratio
indic
synergi
ie
viru
titer
predict
addit
effect
higher
experiment
determin
viru
titer
ratio
indic
antagon
ie
viru
titer
predict
addit
effect
lower
experiment
determin
viru
titer
drug
combin
show
clear
differ
experiment
predict
titer
mark
yellow
ratio
indic
red
mtt
valu
shown
blue
drug
combin
immunolog
toler
neonat
toler
ifnar
mice
highli
suscept
cchfv
infect
inoculum
suffici
initi
product
infect
low
ffu
presum
correspond
infecti
viru
particl
consist
experi
mice
lack
interferon
type
type
ii
receptor
inoculum
ffu
lymphocyt
choriomening
viru
suffici
infect
anim
shown
recent
ifnar
model
mimic
hallmark
human
cchf
diseas
find
extend
detail
immunhistopatholog
analysi
liver
histopatholog
viru
load
measur
antigen
stain
variou
organ
measur
ast
alt
demonstr
liver
major
target
organ
cchfv
although
viru
found
organ
titer
liver
highest
exce
log
ffug
experi
higher
viru
titer
liver
compar
organ
may
explain
ihc
analysi
viru
antigen
reveal
clearli
posit
cell
liver
signal
organ
weak
absent
except
case
ast
alt
valu
reach
ul
ul
respect
demonstr
massiv
liver
cell
damag
howev
alt
specif
organ
ast
also
present
high
level
heart
skelet
muscl
kidney
brain
red
blood
cell
therefor
high
astalt
ratio
may
also
indic
extrahepat
cell
damag
overal
histolog
biochem
find
compat
diagnosi
fulmin
liver
damag
find
also
agreement
patholog
observ
human
cchf
hepatocellular
necrosi
hyperplast
hypertroph
kupffer
cell
mild
absent
inflammatori
cell
infiltr
promin
histopatholog
find
human
two
new
aspect
may
provid
clue
pathophysiolog
cchf
noteworthi
first
necrot
lesion
liver
cchfvinfect
hepatocyt
apoptot
hepatocyt
cluster
may
suggest
cchfvinfect
cell
undergo
apoptosi
necrosi
inflammatori
respons
mild
moder
direct
cytopath
effect
viru
hepatocyt
may
involv
induct
apoptosi
necrosi
importantli
hypothesi
rais
earli
ihc
studi
human
cchf
well
secondli
activ
macrophag
activ
monocytederiv
cell
express
ino
found
liver
cell
may
play
crucial
role
strong
proinflammatori
immun
respons
follow
cchfv
infect
demonstr
signific
increas
serum
proinflammatori
cytokin
chemoattract
molecul
ifnar
mice
well
human
studi
employ
ifnar
mous
model
test
antivir
cchfv
vivo
ribavirin
standard
treatment
human
cchf
although
clinic
efficaci
proven
show
benefici
effect
neonat
mous
model
therefor
first
evalu
ifnar
mous
model
use
drug
surviv
time
prolong
surviv
rate
increas
larg
correspond
result
highdos
challeng
experi
mice
despit
delay
diseas
progress
reduct
viru
load
blood
organ
evidenc
viru
titrat
ihc
ribavirin
abl
prevent
lethal
pathophysiolog
cascad
importantli
figur
treatment
mice
combin
ribavirin
mice
inocul
ip
ffu
viru
administ
twice
daili
per
os
use
stomach
probe
ribavirin
administ
ip
daili
anim
receiv
dose
mg
combin
ribavirin
dose
mg
placebo
control
shown
fig
experi
conduct
parallel
treatment
commenc
h
pi
continu
death
day
mean
standard
deviat
shown
weight
temperatur
vertic
bar
graph
ast
alt
note
log
scale
yaxi
logtransform
viru
titer
blood
repres
mean
valu
durat
treatment
surviv
plot
rang
viremia
detect
limit
immunofocusassay
well
normal
refer
rang
ast
alt
mice
shade
grey
note
two
anim
die
day
detect
viru
organ
blood
astalt
elev
develop
termin
liver
necrosi
mark
monocyt
macrophag
activ
virtual
absenc
viru
organ
demonstr
host
pathway
trigger
viru
mediat
patholog
death
irrespect
presenc
trigger
second
compound
test
arbidol
hydrochlorid
broadspectrum
antivir
drug
clinic
use
flu
arbidol
hydrochlorid
effici
suppress
cchfv
cell
cultur
howev
benefici
effect
ifnar
mous
model
observ
drug
administ
via
rout
higher
dose
previou
studi
show
benefici
effect
influenza
coxsacki
b
hantaan
viru
mice
compound
signific
toxic
higher
concentr
cell
cultur
conceiv
antivir
effect
vitro
least
partial
attribut
gener
cell
toxic
effect
detect
mtt
assay
use
assess
cell
viabil
therefor
might
vitro
data
overestim
true
antivir
effect
drug
cchfv
addit
arbidol
extrem
hydrophob
may
reduc
oral
bioavail
mice
might
worth
test
arbidol
pharmaceut
formul
enhanc
solubl
futur
import
observ
studi
strong
antivir
effect
cchfv
cell
cultur
ifnar
mous
model
compound
shown
highli
activ
rang
virus
vitro
vivo
includ
orthomyxovirus
arenavirus
bunyavirus
genera
hantaviru
phleboviru
therefor
activ
cchfv
bunyaviru
genu
nairoviru
unexpect
howev
view
low
lack
potenc
ribavirin
arbidol
vivoboth
almost
ic
ic
valu
high
vivo
potenc
surpris
ic
cchfv
time
lower
ic
valu
bunyavirus
may
indic
viru
particularli
sensit
even
given
day
expect
time
death
anim
surviv
hardli
show
sign
diseas
given
immedi
postexposur
drug
suppress
viru
replic
level
requir
elicit
antibodi
could
reduc
dose
factor
mg
drug
still
show
postexposur
efficaci
mode
action
cchfv
known
analog
segment
neg
strand
virus
may
incorpor
nascent
rna
strand
inhibit
strand
extens
induc
lethal
mutagenesi
ribavirin
act
cchfv
still
known
although
drug
clinic
use
sinc
decad
sever
mechan
propos
virus
may
incorpor
viru
rna
caus
lethal
mutagenesi
interfer
cap
inhibit
viral
rna
polymeras
inhibit
host
cell
enzym
inosin
monophosph
dehydrogenas
impdh
result
reduc
gtp
level
time
weaker
impdh
inhibitori
effect
suggest
impdh
major
target
enzym
given
mode
action
drug
poorli
understood
difficult
predict
interact
howev
ribavirin
standard
drug
treatment
cchf
combin
treatment
would
obviou
option
clinic
practic
experi
suggest
drug
act
antagonist
manner
vitro
vivo
accord
bliss
independ
model
even
evid
synergist
interact
vitro
experi
anim
model
point
benefici
rather
advers
interact
vivo
conclus
data
hold
promis
clinic
efficaci
combin
treatment
human
cchf
